As per Fortune Business Insights, the preimplantation genetic testing market size was valued at USD 928.78 billion in 2025 and is projected to grow from USD 995.65 billion in 2026 to USD 1,736.79 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 7.2% during the forecast period.

The global Preimplantation Genetic Testing Market is experiencing substantial expansion, driven by rising maternal age, increasing utilization of assisted reproductive technologies, and growing clinical demand for high-accuracy embryo screening.

Market Overview

The preimplantation genetic testing sector encompasses specialized laboratory assays, next-generation sequencing platforms, and biopsy workflows utilized during in vitro fertilization to screen embryos for chromosomal abnormalities, monogenic disorders, and structural rearrangements. Supported by specialized fertility clinics and advanced genomic laboratories, these procedures maximize implantation success rates and reduce the risk of miscarriage.

Market Insights

Industry insights highlight an accelerated adoption of next-generation sequencing and artificial intelligence-assisted embryo assessment tools, enabling laboratories to detect mosaicism with superior sensitivity. Furthermore, strategic partnerships between fertility clinics and diagnostics firms continue to streamline genetic testing workflows and expand regional accessibility.

Market Trends

For detailed market insights, visit the Preimplantation Genetic Testing Market reports: https://www.fortunebusinessinsights.com/preimplantation-genetic-testing-market-111730

Market Growth Factors

For request sample reports: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/preimplantation-genetic-testing-market-111730

Competitor Analysis

The competitive landscape of the market features prominent genomics laboratories, biotechnology enterprises, and specialized fertility diagnostics providers focusing heavily on technological innovation, workflow automation, and strategic partnerships. Key industry participants invest significantly in high-throughput sequencing research, proprietary bioinformatics software, and global clinical validation to secure competitive advantages and maintain strong market positioning.